Key result
Adjunctive immunosuppression shows no benefit over corticosteroids alone for preventing cardiac sarcoidosis relapse.
Why the study?
Cardiac sarcoidosis is a life-threatening condition lacking clear recommendations, warranting an updated review of corticosteroid and immunosuppressive therapies.
Do corticosteroids and/or immunosuppressive therapies improve outcomes in patients with cardiac sarcoidosis?
Systematic Review
Do corticosteroids and/or immunosuppressive therapies improve outcomes in patients with cardiac sarcoidosis?
Answers are grounded in this paper and cite their sources.
Corticosteroids appear to have a positive impact on left ventricular function and arrhythmias in cardiac sarcoidosis, but high-quality evidence and data on adjunctive immunosuppressive therapies are lacking.
BACKGROUND: Cardiac sarcoidosis (CS) is a life-threatening condition in which clear recommendations are lacking. We aimed to systematically review the literature on cardiac sarcoidosis treated by corticosteroids and/or immunosuppressive agents in order to update the management of CS. METHODS: Using PubMed, Embase and Cochrane Library databases, we found original articles on corticosteroid and standard immunosuppressive therapies for CS that provided at least a fair Scottish Intercollegiate Guidelines Network (SIGN) overall assessment of quality and we analysed the relapse rate, major cardiac adverse events (MACEs) and adverse events. We based our methods on the PRISMA statement and checklist. RESULTS: We retrieved 21 studies. Mean quality provided by SIGN assessment was 6.8 out of 14 (range 5-9). Corticosteroids appeared to have a positive impact on left ventricular function, atrioventricular block and ventricular arrhythmias. For corticosteroids alone, nine studies (45%, n=351) provided data on relapses, representing an incidence of 34% (n=119). Three studies (14%, n=73) provided data on MACEs (n=33), representing 45% of MACEs in patients treated by corticosteroid alone. Nine studies provided data on adjunctive immunosuppressive therapy, of which four studies (n=78) provided data on CS relapse, representing an incidence of 33% (n=26). Limitations consisted of no randomised control trial retrieved and unclear data on MACEs in patients treated by combined immunosuppressive agents and corticosteroids. CONCLUSION: Corticosteroids should be started early after diagnosis but the exact scheme is still unclear. Studies concerning adjunctive conventional immunosuppressive therapies are lacking and benefits of adjunctive immunosuppressive therapies are unclear. Homogenous data on CS long-term outcomes under corticosteroids, immunosuppressive therapies and other adjunctive therapies are lacking.
No takes yet. Share an insight, caveat, or question.
Stievenart et al. (2021) conducted a systematic review in Cardiac sarcoidosis. Corticosteroids and/or immunosuppressive agents was evaluated on Relapse rate, major cardiac adverse events (MACEs) and adverse events. In a systematic review of cardiac sarcoidosis, corticosteroids alone were associated with a 34% relapse incidence, while adjunctive immunosuppressive therapy had a 33% relapse incidence.
Synapse has enriched 10 related papers. Consider them for comparative context: